Korean Circ J.  1983 Jun;13(1):185-193. 10.4070/kcj.1983.13.1.185.

Vasodilator Therapy in Children with Congestive Heart Failure

• Yoon YS
• Hong CY
• Chung KJ

• KMID: 2229786
• DOI: http://doi.org/10.4070/kcj.1983.13.1.185

Abstract

Patients with severe congestive heart failure due to rheumatic heart disease generally have both reduced cardiac output and increased pulmonary and systemic venous pressures. A study was therefore made of the use of vasodilator therapy with orally administered hydralazine, which acts on arteriolar resistance vessels and thus reduces afterload. 55 children aged from 4 years old to 15 year old were divided into two groups. Group I received oral hydralazine(4mg/kg/kay in 4 divided doses) in addition to digoxin therapy for mean duration of 10.5 months. Group II received oral digoxin only. The hemodynamic results using M-mode echocardiography, chest X-ray, and EKG between two groups were analyzed. 1) 4(78%) of 55 patients had only mitral valve involvement and another 12 patients had double valve involvement and all the patients belonged to functional class III or IV fo New York heart Association. 2) Left venticular end-diastolic dimensions and the height of R in V6 on EKG were not changed significantly in both groups. 3) Shortening fraction, LPEP/LVET, and RPEP/RVET were markedly improved in both groups, but the degree of improvement in group I was more significant than in group II. 4) 21(80%) of 26 patients in group I showed significant improvement in functional class(t=1.92, 0.05

MeSH Terms

Adolescent
Cardiac Output
Child*
Child, Preschool
Digoxin
Echocardiography
Electrocardiography
Estrogens, Conjugated (USP)*
Heart
Heart Failure*
Hemodynamics
Humans
Hydralazine
Mitral Valve
Rheumatic Heart Disease
Thorax
Venous Pressure
Digoxin
Estrogens, Conjugated (USP)
Hydralazine